U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172919) titled 'A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation' on Sept. 08.
Brief Summary: The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
Study Start Date: Oct. 20
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: Sotorasib
Sotorasib will be administered orally as a tablet.
DRUG: Panitumumab
Panitumumab will be administered as an IV infusion.
Recrui...